VRAX logo

Virax Biolabs Group NasdaqCM:VRAX Stock Report

Last Price

US$2.14

Market Cap

US$10.5m

7D

7.5%

1Y

-12.0%

Updated

12 Nov, 2024

Data

Company Financials

Virax Biolabs Group Limited

NasdaqCM:VRAX Stock Report

Market Cap: US$10.5m

VRAX Stock Overview

A biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology.

VRAX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Virax Biolabs Group Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Virax Biolabs Group
Historical stock prices
Current Share PriceUS$2.14
52 Week HighUS$9.00
52 Week LowUS$0.60
Beta1.92
11 Month Change19.55%
3 Month Change23.70%
1 Year Change-11.97%
33 Year Changen/a
5 Year Changen/a
Change since IPO-98.82%

Recent News & Updates

Recent updates

Virax stock soars 40% on launch of monkeypox rapid test kits

Sep 20

Virax Biolabs soars 37% on launch of real-time PCR test for monkeypox in Europe

Jul 26

Shareholder Returns

VRAXUS HealthcareUS Market
7D7.5%4.7%3.9%
1Y-12.0%6.1%33.2%

Return vs Industry: VRAX underperformed the US Healthcare industry which returned 8.3% over the past year.

Return vs Market: VRAX underperformed the US Market which returned 36.9% over the past year.

Price Volatility

Is VRAX's price volatile compared to industry and market?
VRAX volatility
VRAX Average Weekly Movement53.9%
Healthcare Industry Average Movement7.2%
Market Average Movement6.2%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market3.0%

Stable Share Price: VRAX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VRAX's weekly volatility has increased from 32% to 54% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201317James Fosterviraxbiolabs.com

Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual’s immunological profiling data and provide advice on the users’ immune system.

Virax Biolabs Group Limited Fundamentals Summary

How do Virax Biolabs Group's earnings and revenue compare to its market cap?
VRAX fundamental statistics
Market capUS$10.46m
Earnings (TTM)-US$6.73m
Revenue (TTM)US$156.42k

59.4x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VRAX income statement (TTM)
RevenueUS$156.42k
Cost of RevenueUS$105.83k
Gross ProfitUS$50.59k
Other ExpensesUS$6.78m
Earnings-US$6.73m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.55
Gross Margin32.34%
Net Profit Margin-4,304.81%
Debt/Equity Ratio0%

How did VRAX perform over the long term?

See historical performance and comparison